Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Go back to Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026| (NYSE: BHVN) | Delayed: 11.75 -0.06 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.81 | 52 Week High | $ | |||
| Open | $11.90 | 52 Week Low | $ | |||
| Day High | $12.16 | P/E | N/A | |||
| Day Low | $11.63 | EPS | $ | |||
| Volume | 1,443,718 | |||||



